1/22
10:52 am
ipsc
Century Therapeutics, Inc. (NASDAQ: IPSC) had its "buy" rating re-affirmed by analysts at Guggenheim.
Low
Report
Century Therapeutics, Inc. (NASDAQ: IPSC) had its "buy" rating re-affirmed by analysts at Guggenheim.
1/22
08:14 am
ipsc
Century Therapeutics, Inc. (NASDAQ: IPSC) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $5.00 price target on the stock.
Medium
Report
Century Therapeutics, Inc. (NASDAQ: IPSC) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $5.00 price target on the stock.
1/21
08:13 am
ipsc
Century Therapeutics Announces Investigator-Initiated Phase 1/2 Trial of its iPSC-derived iNK Cell Therapy CNTY-101 in B-cell Mediated Autoimmune Diseases Sponsored by Internationally Renowned Key Opinion Leaders [Yahoo! Finance]
Medium
Report
Century Therapeutics Announces Investigator-Initiated Phase 1/2 Trial of its iPSC-derived iNK Cell Therapy CNTY-101 in B-cell Mediated Autoimmune Diseases Sponsored by Internationally Renowned Key Opinion Leaders [Yahoo! Finance]
1/21
07:00 am
ipsc
Century Therapeutics Announces Investigator-Initiated Phase 1/2 Trial of its iPSC-derived iNK Cell Therapy CNTY-101 in B-cell Mediated Autoimmune Diseases Sponsored by Internationally Renowned Key Opinion Leaders
Low
Report
Century Therapeutics Announces Investigator-Initiated Phase 1/2 Trial of its iPSC-derived iNK Cell Therapy CNTY-101 in B-cell Mediated Autoimmune Diseases Sponsored by Internationally Renowned Key Opinion Leaders
12/30
12:28 pm
ipsc
Century Therapeutics, Inc. (NASDAQ: IPSC) had its price target lowered by analysts at Piper Sandler from $12.00 to $4.00. They now have an "overweight" rating on the stock.
Low
Report
Century Therapeutics, Inc. (NASDAQ: IPSC) had its price target lowered by analysts at Piper Sandler from $12.00 to $4.00. They now have an "overweight" rating on the stock.
12/17
07:47 am
ipsc
Shinobi Strengthens Leadership to Propel Scalable Immune-Evasive Cell Therapies to the Clinic [Yahoo! Finance]
Medium
Report
Shinobi Strengthens Leadership to Propel Scalable Immune-Evasive Cell Therapies to the Clinic [Yahoo! Finance]